Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS)
作者： Lamiae Grimaldi-Bensouda , Frederic Rouillon , Bernard Astruc , Michel Rossignol , Jacques Benichou
DOI: 10.1016/J.SCHRES.2011.10.022
关键词:
摘要: Abstract Objective The primary aim of this study was to compare the impact risperidone long-acting injectable (R-LAI) other antipsychotics on rates hospitalisation in real-life settings. Method Cohort for General Schizophrenia (CGS) followed 1859 patients diagnosed with schizophrenia (DSM-IV) from 177 psychiatric wards public and private hospitals across France over a mean period 12 months. These were ambulatory or had been hospitalised less than 93 days at entry. Recruitment stratified second-generation antipsychotic use. A multivariate Poisson regression adjusted confounding propensity scores allowing autocorrelation used calculation relative 95% confidence intervals. Results age participants 37.65 years, 68.3% male 36.7% Altogether, accumulated 796 hospital stays (53.4 per 100 person-years). R-LAI slightly younger more often past 12 months compared non-R-LAI users. analysis showed use be associated lower rate future hospitalisation: 0.66 [0.46–0.96] use, 0.53 [0.32–0.88] LAIs. Conclusion Use non-use R-LAI.
elsevier.com
schres-journal.com 参考文章(30)
Bossie Ca, Macfadden W, Thomas Haskins J, Ma Yw, Alphs L, A Prospective Study Comparing the Long-term Effectiveness of Injectable Risperidone Long-acting Therapy and Oral Aripiprazole in Patients with Schizophrenia. Psychiatry (Edgmont (Pa. : Township)). ,vol. 7, pp. 23- 31 ,(2010)
Daniel L. Segal, Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) The Corsini Encyclopedia of Psychology. pp. 1- 3 ,(2010) , 10.1002/9780470479216.CORPSY0271
Simon Gilbody, Anne-Marie Bagnall, Lorna Duggan, Arja Tuunainen, Risperidone versus other atypical antipsychotic medication for schizophrenia Cochrane Database of Systematic Reviews. ,vol. 9, pp. 002306- ,(2016) , 10.1002/14651858.CD002306.PUB2
Ya Mei Bai, Tzu Ting Chen, Jen-Yeu Chen, Wen-Ho Chang, Bojian Wu, Chih Hung Hung, Wen Kuo Lin, Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. The Journal of Clinical Psychiatry. ,vol. 68, pp. 1218- 1225 ,(2007) , 10.4088/JCP.V68N0808
Christine Montout, Francoise Casadebaig, Rajaa Lagnaoui, Helene Verdoux, Alain Philippe, Bernard Begaud, Nicholas Moore, Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients Schizophrenia Research. ,vol. 57, pp. 147- 156 ,(2002) , 10.1016/S0920-9964(01)00325-5
H. A. Nasrallah, The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatrica Scandinavica. ,vol. 115, pp. 260- 267 ,(2007) , 10.1111/J.1600-0447.2006.00982.X
J. M. Olivares, J. Peuskens, J. Pecenak, S. Resseler, A. Jacobs, K. S. Akhras, , Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Current Medical Research and Opinion. ,vol. 25, pp. 2197- 2206 ,(2009) , 10.1185/03007990903149306
Y. Lecrubier, D. Sheehan, T. Hergueta, E. Weiller, The mini international neuropsychiatric interview European Psychiatry. ,vol. 13, ,(1998) , 10.1016/S0924-9338(99)80239-9
Diego Novick, Josep Maria Haro, David Suarez, Eduard Vieta, Dieter Naber, Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study Schizophrenia Research. ,vol. 108, pp. 223- 230 ,(2009) , 10.1016/J.SCHRES.2008.11.007
John E. Overall, Donald R. Gorham, The Brief Psychiatric Rating Scale Psychological Reports. ,vol. 10, pp. 799- 812 ,(1962) , 10.2466/PR0.1962.10.3.799